{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:05:04Z","timestamp":1765040704760,"version":"3.37.3"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1002\/2327-6924.12438","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T10:37:03Z","timestamp":1485859023000},"page":"104-115","source":"Crossref","is-referenced-by-count":1,"title":["Oral antiplatelet agents for the management of acute coronary syndromes"],"prefix":"10.1097","volume":"29","author":[{"given":"Tania","family":"Gesheff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cescelle","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210915","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40262-015-0320-0","article-title":"Crushed versus integral tablets of ticagrelor in ST\u2010segment elevation myocardial infarction patients: A randomized pharmacokinetic\/pharmacodynamic study","volume":"55","author":"Alexopoulos","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"key":"R2-9-20210915","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2010ST\u2010elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"R3-9-20210915","first-page":"e663","article-title":"2012 ACCF\/AHA focused update incorporated into the ACCF\/AHA 2007 guidelines for the management of patients with unstable angina\/non\u2010ST\u2010elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"Anderson","year":"2013","journal-title":"Circulation"},{"issue":"7329","key":"R4-9-20210915","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.","volume":"324","year":"2002","journal-title":"British Medical Journal"},{"key":"R5-9-20210915","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non\u2010ST elevation MI: A method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"Journal of the American Medical Association"},{"key":"R7-9-20210915","first-page":"499","article-title":"In\u2010hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE\u2010ACS study","volume":"4","author":"Bagai","year":"2015","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"key":"R8-9-20210915","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.amjcard.2012.10.018","article-title":"Refining the role of antiplatelet therapy in medically managed patients with acute coronary syndrome","volume":"111","author":"Boden","year":"2013","journal-title":"American Journal of Cardiology"},{"key":"R9-9-20210915","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long\u2010term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"R11-9-20210915","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00228-015-1949-1","article-title":"The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: A systematic review","volume":"72","author":"Chandrasekhar","year":"2016","journal-title":"European Journal of Clinical Pharmacology"},{"key":"R12-9-20210915","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual\u2010antiplatelet treatment beyond 1 year after drug\u2010eluting stent implantation (ARCTIC\u2010Interruption): A randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"R13-9-20210915","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second\u2010generation drug\u2010eluting stent implantation followed by 6\u2010 versus 12\u2010month dual antiplatelet therapy: The SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"R15-9-20210915","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1161\/CIRCULATIONAHA.104.494468","article-title":"Molecular regulation of platelet\u2010dependent thrombosis","volume":"112","author":"Freedman","year":"2005","journal-title":"Circulation"},{"key":"R16-9-20210915","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","article-title":"Predictors of hospital mortality in the Global Registry of Acute Coronary Events","volume":"163","author":"Granger","year":"2003","journal-title":"Archives of Internal Medicine"},{"key":"R17-9-20210915","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"R18-9-20210915","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double\u2010blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"R19-9-20210915","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: Results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR Platelets) Study","volume":"111","author":"Gurbel","year":"2005","journal-title":"Circulation"},{"key":"R20-9-20210915","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST\u2010segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST\u2010segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"Hamm","year":"2011","journal-title":"European Heart Journal"},{"key":"R21-9-20210915","doi-asserted-by":"crossref","first-page":"017104","DOI":"10.1088\/1752-7155\/10\/1\/017104","article-title":"Changes in CYP2C19 enzyme activity evaluated by the [(13)C]\u2010pantoprazole breath test after co\u2010administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity","volume":"10","author":"Harvey","year":"2016","journal-title":"Journal of Breath Research"},{"key":"R22-9-20210915","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/eci.12550","article-title":"Morphine decreases ticagrelor concentrations but not its antiplatelet effects: A randomized trial in healthy volunteers","volume":"46","author":"Hobl","year":"2015","journal-title":"European Journal of Clinical Investigation"},{"key":"R23-9-20210915","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00392-015-0927-z","article-title":"Morphine interaction with prasugrel: A double\u2010blind, cross\u2010over trial in healthy volunteers","volume":"105","author":"Hobl","year":"2015","journal-title":"Clinical Research in Cardiology"},{"key":"R24-9-20210915","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/FJC.0b013e3181d9f81f","article-title":"Preventing serious sequelae after an acute coronary syndrome: The consequences of thrombosis versus bleeding with antiplatelet therapy","volume":"55","author":"Islam","year":"2010","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"R25-9-20210915","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.111.082727","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack","volume":"125","author":"James","year":"2012","journal-title":"Circulation"},{"key":"R26-9-20210915","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0895-4356(02)00405-5","article-title":"Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction","volume":"55","author":"Kaplan","year":"2002","journal-title":"Journal of Clinical Epidemiology"},{"key":"R27-9-20210915","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: The randomized, double\u2010blind, placebo\u2010controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2015","journal-title":"European Heart Journal"},{"key":"R28-9-20210915","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"key":"R29-9-20210915","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI Guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"R30-9-20210915","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/09537100903046317","article-title":"Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects","volume":"20","author":"Li","year":"2009","journal-title":"Platelets"},{"key":"R31-9-20210915","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug\u2010eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"R32-9-20210915","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long\u2010term therapy in patients undergoing percutaneous coronary intervention: The PCI\u2010CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"R33-9-20210915","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/TCRM.S92222","article-title":"New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism","volume":"11","author":"Mekaj","year":"2015","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"R35-9-20210915","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST\u2010segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"R36-9-20210915","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"R37-9-20210915","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX\u20102 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"Journal of the American Medical Association"},{"key":"R38-9-20210915","first-page":"e362","article-title":"2013 ACCF\/AHA Guideline for the management of ST\u2010elevation myocardial infarction: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"R40-9-20210915","first-page":"555","article-title":"Dyspnoea management in acute coronary syndrome patients treated with ticagrelor","volume":"4","author":"Parodi","year":"2015","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"key":"R41-9-20210915","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: The MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"R42-9-20210915","first-page":"509","article-title":"Predictors of one\u2010year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long\u2010term follow up of antithrombotic management patterns in acute coronary syndrome patients) study","volume":"4","author":"Pocock","year":"2015","journal-title":"European Heart Journal: Acute Cardiovascular Care"},{"key":"R43-9-20210915","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"R44-9-20210915","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST\u2010segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"R45-9-20210915","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR\u2010SAFE: A randomized, double\u2010blind, placebo\u2010controlled trial of 6 vs. 12 months of clopidogrel therapy after drug\u2010eluting stenting","volume":"36","author":"Schulz\u2010Schupke","year":"2015","journal-title":"European Heart Journal"},{"key":"R46-9-20210915","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/17425255.2014.856883","article-title":"Antiplatelet drug interactions with proton pump inhibitors","volume":"10","author":"Scott","year":"2014","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"R47-9-20210915","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/157340312803217247","article-title":"Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI","volume":"8","author":"Srikanth","year":"2012","journal-title":"Current Cardiology Reviews"},{"key":"R48-9-20210915","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST\u2010segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"European Heart Journal"},{"key":"R49-9-20210915","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"R50-9-20210915","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.amjcard.2011.07.015","article-title":"Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy)","volume":"108","author":"Storey","year":"2011","journal-title":"American Journal of Cardiology"},{"key":"R51-9-20210915","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin\u2010receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"R52-9-20210915","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"R53-9-20210915","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"R54-9-20210915","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.atherosclerosis.2015.10.005","article-title":"Impact of atorvastatin or rosuvastatin co\u2010administration on platelet reactivity in patients treated with dual antiplatelet therapy","volume":"243","author":"Verdoia","year":"2015","journal-title":"Atherosclerosis"},{"key":"R55-9-20210915","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"R56-9-20210915","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12 receptor\u2010mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin\u2010treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"European Heart Journal"},{"key":"R57-9-20210915","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio\u2010Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"European Heart Journal"},{"key":"R58-9-20210915","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"R59-9-20210915","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2011.96","article-title":"The evolution of antiplatelet therapy in cardiovascular disease","volume":"8","author":"Yousuf","year":"2011","journal-title":"Nature Reviews Cardiology"},{"key":"R60-9-20210915","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST\u2010segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"New England Journal of Medicine"}],"container-title":["Journal of the American Association of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2F2327-6924.12438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01741002-201702000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T13:22:52Z","timestamp":1631712172000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01741002-201702000-00009"}},"subtitle":["A review for nurses and allied healthcare professionals"],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/2327-6924.12438","relation":{},"ISSN":["2327-6924"],"issn-type":[{"type":"print","value":"2327-6924"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}